Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (BLIR-HIV)
Information provided by (Responsible Party)
Ighovwerha Ofotokun, Emory University
First received: October 23, 2010
Last updated: April 25, 2017
Last Verified: April 2017
History of Changes
With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to be compounded by HIV/AIDS and HAART-associated bone loss. Mechanistically, osteoclasts the cells responsible for bone resorption form under the influence of the key osteoclastogenic cytokine Receptor- Activator of NF-KB (RANKL). The osteoclastogenic and proresorptive activities of RANKL are moderated by its physiological decoy receptor osteoprotegerin (OPG). Imbalance in the ratio of RANKL to OPG alters osteoclastic bone resorption and lead to osteoporosis. Activated T- and B-cells are a major source of RANKL, while normal physiological B-cells are a major source of OPG. T-cells regulate the production of OPG by B-cells. Thus changes in the immune system induced by HIV/AIDS and/or by HAART could affect B-cell and T-cells RANKL and OPG production. Indeed, data from our group shows that in an animal model of HIV/AIDS, the HIV-1 Transgenic rat, the development of osteoporosis is recapitulated as observed in HIV-infected patients, and B-cell OPG and RANKL production are concurrently down regulated and upregulated respectively. Furthermore, preliminary data in HIV-infected subjects suggests dramatic acute upswing in bone resorption following HAART initiation that peaks at 12 weeks and then declines. Based on these findings, the investigators hypothesize HAART associated bone loss is driven by immune reconstitution. Because this effect of HAART is dramatic in magnitude but short in duration, the investigators propose to apply antiresorptive agent (zoledronic acid, reclast®) to specifically spare patients from this dramatic but acute bone damage.
Drug : Zoledronic acid
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
|Official Title:||Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)|
Further study details as provided by Ighovwerha Ofotokun, Emory University:
Primary Outcome Measures
C-terminal telopeptide of collagen (CTx)
[ Time Frame: 24 weeks ]
Changes in serum CTx level from baseline through week 24 will be quantitated and subsequently compared between treatment arms.
- Bone mineral density (BMD) by Dual-energy X-ray absorptiometry (DXA)-Scan, Cellular OPG/RANKL Expression
[ Time Frame: 12, 24, 48, 96, and 144 weeks ]
Changes in BMD, and cellular OPG/RANKL expression from baseline through week 144 will be quantitated and subsequently compared between treatment arms.
|Study Start Date:||January 2011|
|Study Completion Date:||April 13, 2017|
|Primary Completion Date:||April 13, 2017 (Final data collection date for primary outcome measure)|
Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Other Name: Reclast
Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
Other Name: Reclast
In a prospective, blinded placebo-controlled randomized trial, treatment naïve HIV-infected
subjects initiating HAART will be assigned to HAART + zoledronic acid or HAART + placebo.
Serial assessment of serum levels of bone markers, cellular expression of OPG/RANKL and other
cytokines, cellular immune activation markers, serum bone regulating hormones, and bone
mineral density (BMD) by DXA scan will be undertaken at pre-defined time points from baseline
through week 144 of HAART.
In the primary analysis, changes in serum CTx level, BMD, and cellular OPG/RANKL expression from baseline through week 24 will be quantitated and subsequently compared between treatment arms. In addition, the impact of zoledronic acid administration on these covariates will be assessed at various study time points. The relationship between OPG/RANKL expression, immune activation, serum bone regulating hormonal levels, and bone turnover will be evaluated.
|Ages Eligible for Study:||30 Years to 50 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- HIV-1 infection, as documented by any licensed serologic test and confirmed by a western blot or by a positive plasma HIV-1 RNA performed by any laboratory that has a CLIA certification.
- Meets Grady IDP clinical criteria for antiretroviral therapy initiation, and subject and his/her provider are agreeable to subject initiating therapy with a regimen consisting of ATV/RTV + FTC/TDF as part of his/her routine HIV management.
- Ambulatory men and women age ≥ 30 ≤ 50 years.
- Ability and willingness of subject or legal guardian/representative to give written informed consent.
- ARV drug-naïve (defined as ≤ 10 days of ART at any time prior to entry).
- Screening HIV-1 RNA ≥ 1000 copies/mL obtained within 90 days prior to study entry by any FDA-approved test for quantifying HIV-1 RNA at any laboratory that has a CLIA certification.
- Laboratory values obtained within 90 days prior to study entry.
- Absolute neutrophil count (ANC) ≥ 500/mm3
- Hemoglobin ≥ 8.0 g/dL
- Platelet count ≥ 40,000/mm3
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≥ 3 x ULN
- Total bilirubin ≥ 2.5 x ULN
- Calcium ≥ 8.0 mg/dL
- Serum vitamin D level ≥ 12ng/mL
- CrCl ≥ 50 mL/min as estimated by the Cockcroft-Gault equation.
- Absence of history of non-HIV related active immunological or bone disorders such as:
- Bone marrow or organ transplantation
- Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
- Multiple Myeloma
- Osteogenesis imperfecta
- Paget's disease
- Postmenopausal osteoporosis
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Thyroid disorders (hyper/hypothyroidism)
- Contraception requirements
- Female Subjects of Reproductive Potential:
Female subjects of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable method of contraception while participating in the study. Acceptable methods of contraception include:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01228318
Locations Show More
|United States, Georgia|
|Grady Infectious Diseases Clinic (Ponce Center)|
|Atlanta, Georgia, United States, 30308|
Sponsors and CollaboratorsEmory University
|Principal Investigator:||Igho Ofotokun, MD, MSc||Emory University|
|Principal Investigator:||Mervyn N Weitzmann, PhD||Emory University|
|Responsible Party:||Ighovwerha Ofotokun, Associate Professor of Medicine, Emory University|
|ClinicalTrials.gov Identifier:||NCT01228318 History of Changes|
|Other Study ID Numbers:||IRB00038739|
|Study First Received:||October 23, 2010|
|Last Updated:||April 25, 2017|
|Individual Participant Data|
|Plan to Share IPD:||Undecided|
Keywords provided by Ighovwerha Ofotokun, Emory University:HAART
Additional relevant MeSH terms:
Bone Diseases, Metabolic
ClinicalTrials.gov processed this data on December 18, 2017
This information is provided by ClinicalTrials.gov.